LEO Pharma

Timber Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for orphan dermatologic diseases. The company focuses on creating non-systemic therapies for rare skin conditions, including congenital ichthyosis and various forms of sclerotic skin diseases. Its investigational products are supported by extensive clinical experience and established safety profiles. Timber's notable late-stage program is TMB-001, while TMB-003 represents its earlier-stage development efforts.

SkinVision is an awareness and tracking solution that supports individuals with the early recognition of melanoma, squamous cell carcinoma, basal cell carcinoma and precancerous actinic keratosis. SkinVision is the first certified skin cancer application globally based on extensive clinical trials in partnership with the university clinic of Ludwig Maximilian University (LMU) in Munich in 2013, published in the JEADV in 2014. The company has built up a customer portfolio of 1,200,000 users globally and a database of 3,5 million pictures of suspicious skin conditions.

NØIE is a skincare company that offers personalized skincare products and solutions for dry skin, acne, eczema, psoriasis, and more. An algorithm is used in the company's skin test to assign customers to their skin family and recommend customized products to suit their skin. Additionally, CO2-neutral deliveries are provided, compensating for carbon emissions generated during the shipping process by planting trees in Denmark. The company aims to improve the quality of life for each individual with skin issues. NØIE was founded in 2019 and is headquartered in Copenhagen, Denmark.

SkinVision is an awareness and tracking solution that supports individuals with the early recognition of melanoma, squamous cell carcinoma, basal cell carcinoma and precancerous actinic keratosis. SkinVision is the first certified skin cancer application globally based on extensive clinical trials in partnership with the university clinic of Ludwig Maximilian University (LMU) in Munich in 2013, published in the JEADV in 2014. The company has built up a customer portfolio of 1,200,000 users globally and a database of 3,5 million pictures of suspicious skin conditions.

Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus. On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.